India's pharmaceutical industry is seeking urgent engagement with the US administration following former President Donald Trump's announcement of a new phased tariff regime targeting imported generic medicines. The move, intended to "RESHORE Generic Pharmaceutical Production into America," has significant implications for India, which serves as the largest pharmaceutical export market for the United States.
Trump's Tariff Plan Details
In a statement, Trump outlined a tariff schedule for generic drugs: they will remain tariff-free until August 1, 2028. After this date, a 100% tariff will be imposed for one year, escalating to 200% thereafter. This policy aims to incentivize pharmaceutical companies to establish or expand manufacturing facilities within the US, with penalties for those failing to do so during the transition period. The policy explicitly excludes patented, branded, and innovative medicines, which will continue under existing trade regulations.
The announcement is particularly impactful for India, as the US accounts for nearly a third of India's total drug exports by value. Furthermore, India is estimated to supply between 40-45% of all generic medicines dispensed in the US, making it a crucial component of the American healthcare supply chain.
Indian Pharma's Response and US Investment
The Indian Pharmaceutical Alliance (IPA), representing major Indian drugmakers, quickly responded, asserting India's long-standing role as a reliable supplier of affordable, quality-assured medicines to American patients. Sudarshan Jain, Secretary General of the IPA, highlighted the substantial investments already made by Indian companies in the US.
"India has been a trusted partner in ensuring the supply of affordable and quality-assured medicines for American patients. Leading Indian pharmaceutical companies have a US presence, with over 40 facilities, supporting American jobs and investing in manufacturing, research and resilient supply chains," Jain stated.
He added that the industry is committed to ongoing dialogue with the US administration to foster a stronger partnership and enhance health and medicine security for both nations.
Companies with US Presence
Several prominent Indian pharmaceutical companies, including Sun Pharma, Dr Reddy’s Laboratories, Aurobindo Pharma, Lupin, Zydus Lifesciences, Cipla, and Granules India, derive a significant portion of their revenue from the US market. Many of these firms have proactively established manufacturing plants, research centers, and packaging facilities within the United States, positioning them to adapt to the proposed policy changes by expanding local production.
Granules India, which operates three facilities in the US, expressed its support for strengthening the pharmaceutical supply chain. Priyanka Chigurupati, Executive Director at Granules India, affirmed:
"Granules supports the goal of building a more resilient pharmaceutical supply chain. Through our three US facilities, including one manufacturing facility with the ability to expand capacity, we have invested in strengthening our US footprint and are well positioned to support increased onshoring."
Chigurupati also noted the company's capability for technology transfers for key products, a strategy already in place for business continuity.
Potential Impact on US Healthcare Costs
While supporting supply chain resilience, Granules India cautioned against the potential for unintended consequences. Chigurupati pointed out that generic medicines constitute nearly 90% of prescriptions dispensed in the US but only about 13% of total prescription drug spending. Given that 40-45% of these generics originate from India, any substantial increase in their cost due to tariffs could elevate overall healthcare expenditures and negatively impact patient affordability across the US healthcare system.
The proposed tariffs are not immediate, but the Indian pharmaceutical industry is expected to actively seek greater clarity from the US administration regarding the precise implementation details, including the uniform application across all generic medicines and potential flexibilities for companies with established US manufacturing operations.